| vaccines, attenuated | Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. (12 Dec 1998) |
|---|---|
| vaccines, combined | Two or more vaccines in a single dosage form. (12 Dec 1998) |
| vaccines, conjugate | Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognised by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection. (12 Dec 1998) |
| vaccines, DNA | Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers. (12 Dec 1998) |
| vaccines, inactivated | Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins. (12 Dec 1998) |
| vaccines, synthetic | Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. (12 Dec 1998) |
| malaria vaccines | Vaccines made from antigens arising from any of the four strains of plasmodium which cause malaria in humans, or from p. Berghei which causes malaria in rodents. (12 Dec 1998) |
| viral hepatitis vaccines | Any vaccine raised against any virus or viral derivative that causes hepatitis. (12 Dec 1998) |
| viral vaccines | Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease. (12 Dec 1998) |
| rickettsial vaccines | Vaccines for the prevention of diseases caused by various species of rickettsia. (12 Dec 1998) |
| poliomyelitis vaccines | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
| poliovirus vaccines | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
| haemophilus vaccines | Vaccines or candidate vaccines containing antigenic polysaccharides from haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine. (12 Dec 1998) |
| saids vaccines | Vaccines or candidate vaccines designed to prevent saids (simian acquired immunodeficiency syndrome) and containing inactivated siv or type d retroviruses or some of their component antigens. (12 Dec 1998) |
| hepatitis b vaccines | Vaccines or candidate vaccines containing inactivated hepatitis b or some of its component antigens and designed to prevent hepatitis b. Some vaccines may be recombinantly produced. (12 Dec 1998) |